Figure 3
From: HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension
Inhibition of HDAC6 diminishes PAH-PASMC proliferation and resistance to apoptosis. (A) Proliferation (Ki67) was measured after treatments of PAH-PASMCs with two pharmacological HDAC6 inhibitors (Tubastatin A and ACY-775) or vehicle (DMSO), as well as siHDAC6 or siSCRM (50 nM) for 48 hours. (B) Apoptosis was similarly assessed following HDAC6 inhibition. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.001. Experiments were performed in triplicate in 3 control and 4 PAH-PASMC cell lines.
